Reprogramming Blood Cells into Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) have been successfully employed to treat a variety of diseases in animal studies and clinical trials. Creative Bioarray is committed to expanding methods for reprogramming blood cells into MSCs with therapeutic value, allowing clients to choose the optimal strategy for their specific scientific needs.


MSCs are pluripotent stem cells capable of self-renewal and differentiation into multiple cell types such as osteoblasts, adipocytes, chondrocytes, etc. MSCs have great therapeutic potential in regenerative medicine. To date, there are numerous clinical trials evaluating the therapeutic efficacy of adipose tissue-derived- or bone marrow-derived MSCs in the treatment of various diseases. However, there are still many barriers to the clinical application of adult tissue-derived MSCs, such as low yield, inconsistent stem cell potential, poor implantation and survival after transplantation, and potential safety issues.

MSCs differentiated from ESCs or iPSCs may resemble fetal MSCs in terms of proliferative and regenerative capacity. However, the application of ESC-based therapy faces ethical issues and MHC (major histocompatibility complex) barriers. Reprogramming mature somatic cells to create patient-specific iPSCs opens up new possibilities for regenerative medicine, including MSC-based treatments. In addition, blood cells have been proposed as a promising source of patient-specific MSCs. Direct reprogramming of blood cells to MSCs is another strategy that may have the potential to overcome the limitations of adult MSCs.

Fig 1. In vivo multilineage differentiation capacity of induced MSCs.Fig.1 In vivo multilineage differentiation capacity of induced MSCs. (Meng, 2013)

Our Strategies

Creative Bioarray has developed several cell reprogramming strategies to help clients obtain MSCs, including differentiating iPSCs into MSCs or directly reprogramming blood cells into MSCs.

  • We efficiently generate transgene-free iPSCs from cord blood (CB) CD34+ progenitor cells using SOX2 and OCT4 with optimized episomal vector design, and then induce the generation of MSCs.
  • We reprogram adult peripheral blood mononuclear cells into iPSCs by non-integrating vectors such as Sendai virus and epidermal vectors, and then transform them into therapeutically valuable MSCs in vitro and in vivo.
  • We achieve the efficient generation of human-induced MSCs from CB- or adult peripheral blood (PB)-CD34 cells through episomal vector-mediated transient OCT4 expression and lentiviral vector-mediated OCT4 transduction.


  • Generation of patient-specific MSCs
  • Skeletal regeneration and tissue repair
  • Application in clinical and preclinical studies


  • Efficient vector systems
  • Optimized experimental protocol
  • Advanced research platform

Creative Bioarray is focused on developing less affordable but more clinically relevant vectors to provide efficient reprogramming of blood cells into MSCs for our customers. Moreover, we have extensive expertise and experience in the field of cell reprogramming. If you have a need for our services, please contact us and send us your scientific requirements.


  1. Meng, X.; et al. Rapid and efficient reprogramming of human fetal and adult blood CD34+ cells into mesenchymal stem cells with a single factor. Cell research. 2013, 23(5): 658-672.
  2. Chen, W.; et al. Generation of mesenchymal stem cells by blood cell reprogramming. Current stem cell research & therapy. 2016, 11(2): 114-121.
For Research Use Only. Not For Clinical Use.